--------------------------------------------------------------------------------

Exhibit 10.1
 
NOVARTIS VACCINES AND DIAGNOSTICS, INC.
5300 Chiron Way
Emeryville, California 94608

June 19, 2015
 
James R. Neal
Vice President, Business Development
XOMA Corporation
2910 Seventh Street
Berkeley, California 94710
 
Re:
Secured Note Agreement – Extension of Maturity Date

 
Dear Jim:
 
As you know, XOMA (US) LLC, a Delaware limited liability company (“XOMA”), and
Novartis Vaccines and Diagnostics, Inc. (f/k/a Chiron Corporation), a Delaware
corporation (together with its affiliates, “NVDI”), are parties to a certain
Secured Note Agreement, dated May 26, 2005 (as amended) (the “Note”) and an
Amended and Restated Research, Development and Commercialization Agreement,
dated July 1, 2008 (the “Amended Agreement”).
 
Currently, NVDI and XOMA are engaged in discussions concerning a possible
restructuring of the debt represented by the Note, and the obligations under the
Amended Agreement.  These discussions include, among other things, consideration
of an amendment to the maturity date of the Note, currently fixed at June 21,
2015.
 
In light of the parties’ discussions and the shared interests the parties have
in negotiating a mutually agreeable restructuring of the Note and the Amended
Agreement, NVDI agrees to, and hereby does, extend the maturity date of the Note
to September 30, 2015.
 
Please confirm that the foregoing is in accordance with your understanding by
acknowledging your agreement in the space provided below.
 

 
Very truly yours,
     
NOVARTIS VACCINES AND DIAGNOSTICS, INC.
     
By:
/s/ Maria A. Rocco-Ichikawa
 
Name:
Maria A. Rocco-Ichikawa
 
Title:
Director Finance NIBR

XOMA (US) LLC
 
/s/ James R. Neal
James R. Neal
Vice President, Business Development
 
 

--------------------------------------------------------------------------------